GlassScriptPhysician profile
Jeffrey Lin
NPI 1639622665
$11,346.76
in general payments reported to CMS, 2019-2025
21 companies · $5,467 in 2025
The $5,467 reported for 2025 was more than what 90% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $582 · 2023: $487 · 2024: $4,633 · 2025: $5,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,450 · Food and Beverage: $1,603 · Travel and Lodging: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,450.00 |
| Food and Beverage | $1,602.64 |
| Travel and Lodging | $534.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $9,485.26 | 2024-2025 | Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $537.98 | 2021-2024 | Nuzyra |
| Abbvie INC. | $264.14 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $140.66 | 2024-2025 | Rebyota |
| La Jolla Pharmaceutical Company | $122.63 | 2021 | |
| Merck Sharp & Dohme LLC | $117.95 | 2022-2024 | Zerbaxa, Dificid, Recarbrio |
| Theratechnologies INC. | $103.19 | 2025 | Trogarzo, Egrifta |
| Amgen INC. | $99.99 | 2022-2025 | Evenity, Krystexxa, Prolia |
| Viiv Healthcare Company | $84.83 | 2021-2023 | Dovato, Cabenuva |
| Astrazeneca Pharmaceuticals LP | $79.32 | 2023 | Evusheld |
| Gilead Sciences, INC. | $46.99 | 2022-2024 | |
| Averitas Pharma INC. | $37.67 | 2023-2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $37.24 | 2023-2024 | Glassia |
| Invivyd INC | $32.14 | 2024 | Pemgarda |
| Lundbeck LLC | $27.70 | 2025 | Vyepti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $27.29 | 2024 | Arikayce |
| Convatec INC. | $25.98 | 2023 | |
| Octapharma USA, INC. | $20.64 | 2023 | Octagam Immune Globulin (Human) |
| Tersera Therapeutics LLC | $19.73 | 2025 | Quzyttir |
| Philips North America LLC | $18.03 | 2024 | (Ak6) Vest Therapy |
| Lilly USA, LLC | $17.40 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.